Teri Foy, PhD, Senior Vice President, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle site lead, and Mike Burgess, MD, PhD, Senior Vice President, Head of Translational Medicine, Bristol Myers Squibb, discuss the challenges, progress, and potential of CAR T-cell therapy. Cell therapy research is now advancing beyond cancer to target cells contributing to other chronic diseases.
Adriana Rossi, MD, assistant professor of medicine, director of CART and the Stem Cell Transplant Clinical Service at the Center of Excellence for Multiple Myeloma, Mount Sinai, New…
Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the…
Barry Paul, MD, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, discusses research related to idecabtagene vicleucel treatment for patients with newly diagnosed multiple myeloma and suboptimal responses…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Doris Hansen, MD, Moffitt Cancer Center, Tampa, Florida, discusses an analysis of pretreatment biomarkers associated with toxicity and durable response related to idecabtagene vicleucel therapy for patients with…
Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
